Stress Urinary Incontinence
Conditions
Keywords
laser treatment
Brief summary
RCT designed to answer the question: Does the application of Erbium: YAG laser treatment to the vagina improve urine control for women with SUI?
Detailed description
This is a double blinded randomized controlled clinical trial with a treatment arm and a sham treatment arm followed by an open label trial at 6 months for any sham treatment arm participants who do not meet treatment success. The primary goal is to compare the subjective success rates for the resolution of UI for the vaginal laser treatment at 6 months. Secondary aims include an assessment of complications, resolution of SUI symptoms (objective and subjective measures), patient bother from UI, quality of life and patient satisfaction. The proposed sample size is 182 patients. At the 6-month post treatment evaluation, the treatment allocation will be unmasked. The trial will be of approximately 3 years in duration (1 year to recruit and 2 years for follow up).
Interventions
PROCEDUREErbium-YAG laser vaginal treatment
Erbium-YAG laser vaginal treatment
Sponsors
Sunnybrook Health Sciences Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
only the care provider (who is not involved with recruitment or evaluation of patients' outcomes) will be aware of the treatment assignments
Intervention model description
RCT
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Female patient, aged 18 years or older at the time of enrollment, 2. primary symptoms of SUI, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation; for a duration of at least 3 months (patient can be rescreened after this time interval has passed). 3. The patient agrees to no new parallel treatment for SUI during the treatment period and the 6 months following it. 4. objective proof of SUI: Observation of urine leakage by cough and valsalva (positive stress test) at a bladder volume of ≤ 300cc 5. Bladder capacity ≥200cc 6. Post void residual ≤100cc with Stage I or lower pelvic organ prolapse
Exclusion criteria
1. Patient is pregnant, lactating, or plans to become pregnant during the course of the Study; or Patient is \<12 months post partum 2. Patient has other predominant type of UI (eg Urgency UI, overflow UI, fistula) 3. Patient has a vaginal condition that does not allow proper vaginal placement of the laser probe in its protective speculum 4. Current chemo/ radiotherapy; history of pelvic radiation 5. Systemic diseases known to affect bladder function (eg Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury) 6. Current or history of urethral diverticulum, prior augmentation cystoplasty, implanted nerve stimulators for bladder symptoms 7. History of synthetic sling 8. Pelvic surgery \< 3 months 9. Current evaluation or treatment for chronic pelvic pain 10. Patient has pelvic organ/ vaginal prolapse extending to or out of the vaginal opening 11. Participation in another treatment intervention that might interfere with the results of this trial 12. Patient has a medical condition or disorder that may limit life expectancy or that may cause non-compliance with the protocol (e.g. unable to perform self-evaluations and/or accurately report medical history, urinary symptoms, and/or data). 13. Patient has ambulatory 24 hour pad test, where the increased pad weight is \< 3 grams. 14. Patient is non-ambulatory (ambulatory with assistive devices allowed)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUI cure | 6 months post treatment | ICIQ questionnaire: The International Consultation on Incontinence Questionnaire (ICIQ) is a subjective measure of the severity of urinary loss and quality of life for those with incontinence. With the short form, there are 3 questions with a multi-choice selection of responses with each response having an assigned score. The total score (additive from the 3 questions) are between 0 - 21. Higher scores are indicative of greater severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse effects | 6,12 24 months post treatment | Number of participants with any reported adverse effects: local burn, bleeding, irritation, infection, vaginal discharge etc. |
Countries
Canada
Contacts
PRINCIPAL_INVESTIGATORPatricia Lee, MD
Sunnybrook Health Sciences Centre
Outcome results
None listed